Latest News and Press Releases
Want to stay updated on the latest news?
-
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert
-
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
-
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
-
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of AI for the Expansion and Optimization of Biomarker Selection for PancAlert
-
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
-
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
-
Mainz Biomed Provides Half Year 2024 Corporate Update - Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study
-
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
-
Mainz Biomed Reports Results of 2024 Annual General Meeting
-
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting